- Home
- MCRB vs PZC Comparison
MCRB vs PZC Comparison
Compare MCRB & PZC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- PZC
- Stock Information
- Founded
- MCRB 2010
- PZC 2002
- Country
- MCRB United States
- PZC United States
- Employees
- MCRB N/A
- PZC N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- PZC Investment Managers
- Sector
- MCRB Health Care
- PZC Finance
- Exchange
- MCRB Nasdaq
- PZC Nasdaq
- Market Cap
- MCRB 141.9M
- PZC 149.1M
- IPO Year
- MCRB 2015
- PZC N/A
- Fundamental
- Price
- MCRB $0.72
- PZC $6.52
- Analyst Decision
- MCRB Hold
- PZC
- Analyst Count
- MCRB 5
- PZC 0
- Target Price
- MCRB $4.00
- PZC N/A
- AVG Volume (30 Days)
- MCRB 840.7K
- PZC 48.2K
- Earning Date
- MCRB 03-13-2025
- PZC 01-01-0001
- Dividend Yield
- MCRB N/A
- PZC 4.68%
- EPS Growth
- MCRB N/A
- PZC N/A
- EPS
- MCRB 0.00
- PZC N/A
- Revenue
- MCRB N/A
- PZC N/A
- Revenue This Year
- MCRB N/A
- PZC N/A
- Revenue Next Year
- MCRB N/A
- PZC N/A
- P/E Ratio
- MCRB $824.00
- PZC N/A
- Revenue Growth
- MCRB N/A
- PZC N/A
- 52 Week Low
- MCRB $0.54
- PZC $6.30
- 52 Week High
- MCRB $1.53
- PZC $8.20
- Technical
- Relative Strength Index (RSI)
- MCRB 46.92
- PZC 28.04
- Support Level
- MCRB $0.69
- PZC $6.56
- Resistance Level
- MCRB $0.76
- PZC $6.74
- Average True Range (ATR)
- MCRB 0.05
- PZC 0.06
- MACD
- MCRB 0.00
- PZC -0.01
- Stochastic Oscillator
- MCRB 53.55
- PZC 1.72
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About PZC PIMCO California Municipal Income Fund III of Beneficial Interest
PIMCO CA Muni Income Fund III operates as a closed-end management investment company. The investment objective of the fund is to seek to provide current income exempt from federal and California income tax. Its portfolio of investments includes investment in different sectors such as education, healthcare, industrial and others.